TMFBiologyFool

Brian Orelli

Somewhere between his graduate thesis on BRCA1, a gene that causes hereditary breast cancer, and his postdoctoral fellowship in DNA repair, Brian realized he enjoyed analyzing other people's data more than running his own experiments. Having gotten his first taste of how to analyze stocks from The Motley Fool many years prior, it was only fitting that he came full circle and started writing about biotech, pharmaceutical, and medical device companies for Fool.com. He also covers the health insurance industry to keep from going into binary-event overload. When not writing at The Motley Fool or trade journals like Nature Biotechnology and BioWorld, Brian can be found coaching soccer or hanging out at the beach in his hometown of San Diego.

TMFBiologyFool’s Activity

Yesterday

Rule Breakers article.

TMFBiologyFool published an update. 3:59 PM

NL

Article

TMFBiologyFool published an article 12:11 PM

3 Ways Intuitive Surgical Inc. Can Slice Up a Solid Third Quarter

Investors should keep an eye on procedure volume, which procedures are being performed, and adoption of the new Xi system.

Thu Oct 16

NL

Article

TMFBiologyFool published an article 4:54 PM

AbbVie Inc to Shire: It's Not You, It's My Country

AbbVie's board recommends that the company not purchase Shire.

Tue Oct 14

NL

Article

TMFBiologyFool published an article 4:22 PM

FDA Sends Mixed Message On Safety of Pfizer inc.'s Chantix

The smoking cessation product might not cause neuropsychiatric events, but the FDA wants more data.

NL

Article

TMFBiologyFool published an article 1:15 PM

Johnson & Johnson and Bristol-Myers Squibb’s New Collaboration Just the Tip of the Iceberg

Bristol-Myers Squibb's Opdivo and Merck's Keytruda are sought after drugs for combination cancer treatments.

Fri Oct 10

NL

Article

TMFBiologyFool published an article 4:10 PM

Gilead Sciences Inc. Gets First Hepatitis C Cocktail Drug Approved

Now the question is how much is Gilead Sciences going to make off Harvoni.

Thu Oct 9

NL

Article

TMFBiologyFool published an article 5:40 PM

Amgen, Inc. Gives AbbVie Inc the Highest Form of Flattery

Amgen is developing a biosimilar of AbbVie's Humira.

Tue Oct 7

NL

Article

TMFBiologyFool published an article 3:10 PM

Bristol-Myers Co Regroups; Hepatitis C Fight With Gilead Sciences Not Over

Bristol-Myers Squibb pulls its FDA application for daclatasvir and asunaprevir. Here are two possible reasons why.

Mon Oct 6

NL

Article

TMFBiologyFool published an article 2:27 PM

Should Pfizer Inc. Buy This Surprisingly Competitive Biotech Stock?

Esperion Therapeutics might be small, but it could pack a mighty punch.

Fri Oct 3

NL

Article

TMFBiologyFool published an article 2:51 PM

Gilead Sciences, Inc. Got 2 Drugs Approved, and Didn't Bother to Tell Anyone

Gilead Science's Tybost and Vitekta are already part of its approved quad pill Stribild.

Tue Sep 30

NL

Article

TMFBiologyFool published an article 3:32 PM

The Next Blue-Chip Stocks: Biogen Idec

Biogen Idec could hit blue chip status, but it's going to take a few years.

NL

Article

TMFBiologyFool published an article 9:05 AM

Big News for These 5 Stocks From ESMO

But smaller biotechs Clovis Oncology and Exelixis also benefit from the big boys' data.

Mon Sep 29

NL

Article

TMFBiologyFool published an article 4:57 PM

Dividend Aristocrats: Time to Buy Johnson & Johnson

Dividend increases make Johnson & Johnson a buy anytime.

Wed Sep 24

NL

Article

TMFBiologyFool published an article 3:42 PM

This Switch Could Make Gilead Sciences, Inc. Stock Billions

Swapping HIV treatments Viread and TAF will extend Gilead Sciences patent protection.

Tue Sep 23

NL

Article

TMFBiologyFool published an article 1:55 PM

These Companies Are Saving Money and Sticking You With a Tax Bill

Moving abroad results in lower tax bills for companies, but investors often have to pay capital-gains taxes when their transactions go through.

Mon Sep 22

NL

Article

TMFBiologyFool published an article 4:54 PM

Regeneron Pharmaceuticals Inc Stock Racks Up Another Win

Bayer and Regeneron Pharmaceuticals get three Eylea approvals in as many months.

NL

Article

TMFBiologyFool published an article 1:45 PM

Surprising Silver Lining for Gilead Sciences, inc. Stock

There's a silver lining in CVS's data on Gilead Sciences' Sovaldi.

Fri Sep 19

NL

Article

TMFBiologyFool published an article 12:54 PM

3 Biotechs Investors Should Watch

The healthcare version of Where the Money Is.

Thu Sep 18

NL

Article

TMFBiologyFool published an article 3:17 PM

5 Things Gilead Sciences, Inc. Management Wants You to Know

Analysis of comments from Gilead Sciences' president and COO.

Tue Sep 16

NL

Article

TMFBiologyFool published an article 2:08 PM

5 Things Arena Pharmaceuticals, Inc.'s Management Wants You to Know

Highlights from Arena Pharmaceuticals' conference call with investors.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 96.90
Player Rank 2329 out of 75065
Score 1413.54
Score Change Today -12.81
Accuracy 65.38%
Active Picks 73
Total Picks 213
Best Pick MYL (+272.27)
Worst Pick ITMN (-437.89)
Average Score per Pick 6.64
Charms Earned 9
Highest Rated Favorite zzlangerhans
Go to TMFBiologyFool’s CAPS page

Boards Stats & Trivia

Three stars, 500 posts CAPS All Star
Board Posts 928
Recs Received 982
People who have rec'd these posts 380
Recs to Posts Ratio (last 30 days) N/A
Threads Started 90
Threads Started Percentage 9.70 %
Most Frequent Board Buying or Selling a Home
Very First Post Re: How many is enough? (6/6/2001)
Percentage of Posts Rec'd 48.17 %
Show TMFBiologyFool’s 10 Latest Posts